Affinage

UBE2C

Ubiquitin-conjugating enzyme E2 C · UniProt O00762

Length
179 aa
Mass
19.7 kDa
Annotated
2026-06-10
100 papers in source corpus 23 papers cited in narrative 23 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

UBE2C (UbcH10) is the cyclin-selective E2 ubiquitin-conjugating enzyme that partners with the APC/C E3 ligase to drive ubiquitination and proteasomal destruction of mitotic substrates including cyclin B, controlling cdc2 inactivation, sister chromatid separation, and anaphase onset (PMID:9122200). Its catalytic cysteine is essential, and a conserved lysine near the active site governs ubiquitin-adduct formation, while a disordered N-terminal extension acts as a regulatory brake on APC/C: removing it broadens substrate lysine targeting, permits destruction of substrates lacking destruction boxes, confers resistance to the APC inhibitors Emi1 and BubR1, and bypasses the spindle assembly checkpoint (PMID:11927573, PMID:18722180). Through APC/C-Cdc20 and APC/C-CDH1 it builds K11-linked chains on cell-cycle regulators, and this activity extends to DEPTOR, whose degradation activates mTORC1 in a UBE2C→CDH1→DEPTOR→mTOR oncogenic cascade demonstrated by genetic epistasis in KrasG12D lung tumors (PMID:36548081). Overexpression of UBE2C causes precocious cyclin B degradation, supernumerary centrioles, aneuploidy, and spontaneous tumors, defining it as a proto-oncogene driving whole-chromosome instability (PMID:20065091). UBE2C transcription is a convergence point for proliferative and oncogenic inputs, directly activated by Cdc20-recruited APC/C-CBP/p300, FOXM1, E2F1/KAT2A, estrogen receptor α, and CRPC-specific MED1/FoxA1 enhancer looping, and repressed by wild-type p53 (PMID:21454660, PMID:21556051, PMID:27129209, PMID:29596365, PMID:31662448, PMID:36292703). Beyond canonical APC/C substrates, UBE2C ubiquitinates p53, pVHL, SIRT1, and SNAT2 in cancer contexts to promote EMT, HIF-1α signaling, autophagy repression, and metabolic reprogramming (PMID:31662448, PMID:30602302, PMID:36930831, PMID:38949026).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 1997 High

    Established UBE2C as the catalytic E2 enzyme that, with the APC/cyclosome, drives mitotic cyclin destruction—answering what enzyme couples ubiquitin transfer to anaphase onset.

    Evidence In vitro ubiquitination in clam oocyte extracts, active-site Cys→Ser mutagenesis, and dominant-negative transfection with cell cycle readout

    PMID:9122200

    Open questions at the time
    • Did not define the structural basis of E2 catalysis
    • Substrate selectivity beyond cyclins A/B not addressed
  2. 2002 High

    Defined the structural determinants of UBE2C catalysis, showing an active-site-proximal lysine controls ubiquitin charging while the N-terminal extension is dispensable for charging.

    Evidence X-ray crystallography at 1.95 Å of the Cys→Ser mutant with lysine mutagenesis and adduct-formation assays

    PMID:11927573

    Open questions at the time
    • Functional role of the disordered N-terminal extension left unexplained
    • No structure in complex with APC/C
  3. 2008 High

    Revealed that the N-terminal extension is a regulatory element restricting APC/C substrate selectivity and enforcing the spindle checkpoint, explaining why APC/C prefers UBE2C.

    Evidence In vitro APC ubiquitination with N-terminal mutants, in vivo spindle-checkpoint bypass, and UbcH10-UbcH5 domain swaps

    PMID:18722180

    Open questions at the time
    • Atomic structure of the N-terminus-APC/C interaction not resolved
    • Chain-linkage specificity not characterized here
  4. 2010 High

    Demonstrated UBE2C is a bona fide proto-oncogene, causally linking its overexpression to chromosomal instability and tumorigenesis in vivo.

    Evidence Graded transgenic mouse overexpression with immunofluorescence, aneuploidy scoring, and tumor incidence/carcinogen challenge

    PMID:20065091

    Open questions at the time
    • Non-APC/C substrates driving transformation not identified
    • Molecular trigger of centriole amplification unresolved
  5. 2010 Medium

    Connected UBE2C dysregulation to viral oncogenesis, showing elevated UbcH10/Cdc20 enables mitotic exit despite DNA damage.

    Evidence Western blot, Cdc20-BubR1 co-IP, and cyclin B stability/cell cycle analysis in HPV-16 E6/E7 keratinocytes

    PMID:20739533

    Open questions at the time
    • Direct transcriptional driver of UbcH10 induction by E6/E7 not defined
    • Single lab
  6. 2011 Medium

    Identified transcriptional and post-translational control of UBE2C levels: Cdc20-APC/C-CBP/p300 transactivates it, MED1 enhancer looping drives it in CRPC, and NO promotes its proteasomal degradation.

    Evidence ChIP, co-IP, promoter-reporter, 3C looping assays, and polyubiquitin detection across cancer cells and a rat carotid-injury model

    PMID:21448667 PMID:21454660 PMID:21556051

    Open questions at the time
    • E3 ligase mediating NO-induced UBE2C degradation unknown
    • Generality of MED1 looping beyond CRPC untested
  7. 2015 Medium

    Extended UBE2C's APC/C role from mitosis to meiosis, showing it gates meiotic exit and can override the spindle checkpoint in oocytes.

    Evidence RNA-injection depletion/overexpression with polar body extrusion and spindle assessment in mouse oocytes

    PMID:26207029

    Open questions at the time
    • Relative contributions of UBE2C vs UBE2S/UBE2D3 not fully separated
    • Substrate specificity in meiosis unaddressed
  8. 2016 Medium

    Placed UBE2C under p53 control and within a broader K11-chain E3 network, identifying SAG/RBX2-CUL5 as an additional E3 partner targeting β-TrCP1.

    Evidence Promoter-reporter, ChIP, reciprocal co-IP, in vitro ubiquitylation, and CHX-chase across cancer cells

    PMID:27129209 PMID:27910872

    Open questions at the time
    • Whether SAG-UBE2C cooperation occurs in physiological cell-cycle context unclear
    • p53-UBE2C axis tested in limited contexts
  9. 2018 Medium

    Defined FOXM1 as a direct transcriptional activator of UBE2C correlated across tumor types, and reported an unusual transcriptional regulatory activity of UBE2C on ZEB1/ZEB2.

    Evidence ChIP, mutagenesis-based reporter assays, expression correlation, and luciferase reporter/migration assays

    PMID:29596365 PMID:31037155

    Open questions at the time
    • The ZEB1/2 finding (#19) is Low-confidence and mechanistically atypical, not independently replicated
    • How an E2 enzyme acts as a transcriptional regulator is unexplained
  10. 2019 Medium

    Established non-APC/C ubiquitination substrates of UBE2C in cancer—p53 and pVHL—linking it to EMT and HIF-1α signaling, with ERα driving its expression.

    Evidence Co-IP ubiquitination assays, ChIP for ERα, siRNA, and xenograft/ex vivo endothelial models

    PMID:30602302 PMID:31662448

    Open questions at the time
    • E3 ligase cooperating with UBE2C on p53/pVHL not identified
    • Direct vs indirect ubiquitination not fully resolved
  11. 2022 Medium

    Identified E2F1/KAT2A-mediated histone acetylation as a transcriptional driver of UBE2C, alongside lower-confidence reports of EGFR-stabilizing glycolytic roles.

    Evidence ChIP/H3K9ac analysis, co-localization, RNA-seq, and co-IP/metabolic assays in cancer cells

    PMID:35837197 PMID:36292703

    Open questions at the time
    • EGFR-binding role (#21) is Low-confidence with limited mechanistic depth
    • Whether KAT2A/E2F1 control is generalizable across tumors untested
  12. 2023 High

    Defined the UBE2C-APC/C-CDH1-DEPTOR-mTOR oncogenic cascade by genetic epistasis and added SIRT1 as a K48-linked degradation substrate controlling autophagy.

    Evidence Conditional double-knockout rescue in KrasG12D mice, K11/K48-linkage ubiquitylation assays, ChIP for H4K16ac, and autophagy flux/xenograft assays

    PMID:36548081 PMID:36930831

    Open questions at the time
    • SIRT1 axis (#15) is single-lab Medium-confidence
    • Whether DEPTOR targeting is APC/C-dependent in non-lung contexts untested
  13. 2024 High

    Revealed substrate-level ubiquitin-linkage crosstalk: UBE2C monoubiquitinates SNAT2 to block its K63-polyubiquitination and endocytosis, driving metabolic and metastatic phenotypes; lower-confidence reports add Notch and NRF2 axes.

    Evidence Site-specific ubiquitination mutagenesis, endocytosis and lymphangiogenesis assays, PDX models, plus reporter/rescue assays for Notch and KEAP1-NRF2

    PMID:38949026 PMID:39032892 PMID:39353974

    Open questions at the time
    • Notch (#20) and NRF2 (#22) axes are Low-confidence with indirect mechanism
    • Cognate E3 ligase for SNAT2 monoubiquitination not defined

Open questions

Synthesis pass · forward-looking unresolved questions
  • How UBE2C achieves substrate selectivity across its many reported non-APC/C targets, and which E3 ligases partner with it in each context, remains unresolved.
  • No structural model of UBE2C bound to APC/C or to alternative E3s
  • Cognate E3s for p53, pVHL, SIRT1, and SNAT2 ubiquitination largely unidentified
  • Mechanism by which UBE2C reportedly regulates transcription (ZEB1/2) is unexplained

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 4 GO:0016740 transferase activity 3 GO:0098772 molecular function regulator activity 1
Pathway
R-HSA-1640170 Cell Cycle 4 R-HSA-1643685 Disease 4 R-HSA-392499 Metabolism of proteins 4 R-HSA-162582 Signal Transduction 2
Partners
APC/CCDC20CDH1DEPTORP53PVHLSAG/RBX2SIRT1
Complex memberships
APC/C

Evidence

Reading pass · 23 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1997 UbcH10 (UBE2C) functions as a cyclin-selective ubiquitin carrier protein (E2) that works with the APC/cyclosome E3 ligase to ubiquitinate cyclin B, driving its destruction. Mutation of the catalytic cysteine to serine creates a dominant-negative that blocks cyclin A and B ubiquitination and destruction in vitro. In mammalian cells, dominant-negative UbcH10 arrests cells in M phase and inhibits anaphase onset, demonstrating roles in both cyclin B degradation (cdc2 inactivation) and sister chromatid separation. In vitro ubiquitination assay in clam oocyte extracts; active-site mutagenesis (Cys→Ser); transfection of dominant-negative into mammalian cells with cell cycle readout Proceedings of the National Academy of Sciences of the United States of America High 9122200
2002 Crystal structure of UbcH10 at 1.95 Å resolution (active-site Cys→Ser mutant) revealed that the N-terminal extension is disordered and that a conserved 3(10)-helix positions a lysine residue near the active site. Mutagenesis showed that this lysine near the active site significantly affects ubiquitin-adduct formation, whereas the N-terminal extension has little effect on ubiquitin charging. X-ray crystallography at 1.95 Å; active-site and lysine mutagenesis with ubiquitin-adduct formation assay The Journal of biological chemistry High 11927573
2008 UbcH10 is preferentially used by the APC/C over other E2s owing to its core E2 domain. Its unique N-terminal extension provides an additional E2-E3 regulatory interaction that limits APC/C activity: mutating the N terminus increases substrate ubiquitination, broadens lysine targeting on substrates, allows destruction of substrates lacking destruction boxes, confers resistance to APC inhibitors Emi1 and BubR1 in vitro, and bypasses the spindle checkpoint in vivo. Fusing the UbcH10 N terminus to UbcH5 restricts ubiquitination without directing APC-specific interactions. In vitro APC ubiquitination assays with UbcH10 N-terminal mutants; spindle checkpoint bypass assay in vivo; domain-swap experiments (UbcH10 N-term fused to UbcH5) Molecular cell High 18722180
2010 Overexpression of UbcH10 in transgenic mice leads to precocious APC/C-mediated degradation of cyclin B, supernumerary centrioles, lagging chromosomes, aneuploidy, and spontaneous tumor formation, identifying UbcH10 as a proto-oncogene that causes whole chromosome instability. Graded transgenic mouse overexpression; immunofluorescence; tumor incidence monitoring; carcinogen challenge The Journal of cell biology High 20065091
2005 A novel UbcH10-binding protein (H10BH) identified by yeast two-hybrid possesses a HECT-like domain, exhibits self-ubiquitinylation activity, binds UbcH10 through residues 235–257, binds cyclin B, and ubiquitinylates cyclin B in vitro, suggesting it acts as a HECT-type E3 using UbcH10 as its cognate E2. Yeast two-hybrid; co-immunoprecipitation; in vitro ubiquitinylation assay of cyclin B Journal of biochemistry Medium 15749827
2011 Cdc20 transcriptionally up-regulates UBE2C expression in a cell-cycle-specific manner. The WD40 domain of Cdc20 is required for this activity, and Cdc20 physically interacts with the APC/C-CBP/p300 complex, which is then recruited to the UBE2C promoter to drive transactivation. Chromatin immunoprecipitation; co-immunoprecipitation; promoter-reporter assays; domain-deletion analysis; cell cycle synchronization The Journal of biological chemistry Medium 21454660
2011 Nitric oxide (NO) decreases UBE2C protein levels in vascular smooth muscle cells by increasing its polyubiquitination, leading to proteasomal degradation of UBE2C. This mechanism is associated with inhibition of VSMC proliferation and reduced neointimal hyperplasia in vivo. Western blotting; immunofluorescent staining; siRNA knockdown; plasmid overexpression; balloon-injury rat carotid artery model; polyubiquitin detection by co-immunoprecipitation Cell biochemistry and biophysics Medium 21448667
2011 PI3K/AKT-phosphorylated MED1 is recruited to CRPC-specific UBE2C enhancers, mediates long-range enhancer-promoter chromatin looping at the UBE2C locus, and recruits FoxA1, RNA polymerase II, and TATA-binding protein, driving UBE2C overexpression in castration-resistant prostate cancer. Chromatin immunoprecipitation; chromosome conformation capture (3C/looping assays); MED1 phosphorylation analysis; siRNA knockdown; cell growth assays The EMBO journal Medium 21556051
2015 UBE2C (Ube2C) and UBE2S, together with UBE2D3, act as the E2 ubiquitin-conjugating enzymes regulating APC/C activity during meiosis I in mouse oocytes. Depletion of Ube2C reduces first polar body extrusion by ~50%; overexpression accelerates and doubles completion. High Ube2C levels override the spindle assembly checkpoint to drive meiotic exit regardless of spindle formation. RNA injection (depletion and overexpression); first polar body extrusion assay; spindle formation assessment in mouse oocytes FASEB journal Medium 26207029
2016 Wild-type p53 transcriptionally represses UBE2C in a p21-E2F4-dependent manner, whereas gain-of-function (GOF) mutant p53 transcriptionally activates UBE2C in an NF-Y-dependent manner. DNA damage-induced wild-type p53 causes spindle assembly checkpoint arrest by repressing UBE2C; GOF mutant p53 causes premature anaphase exit by increasing UBE2C expression. Promoter-reporter assays; chromatin immunoprecipitation; siRNA knockdown; cell cycle analysis after DNA damage (5-fluorouracil) The Journal of biological chemistry Medium 27129209
2016 SAG/RBX2 E3 ligase preferentially binds E2s UBCH10 and UBE2S (which mediate K11-linked ubiquitin chains) rather than CDC34 or UBCH5C (K48 linkage). SAG-CUL5 promotes K11-linked ubiquitylation and degradation of β-TrCP1; silencing of UBCH10 or UBE2S (but not UBCH5C) causes β-TrCP1 accumulation, identifying β-TrCP1 as a physiological substrate of the SAG-UBCH10/UBE2S axis. Co-immunoprecipitation; in vitro ubiquitylation assay; siRNA knockdown; protein half-life (CHX chase) assay Scientific reports Medium 27910872
2018 FOXM1 directly binds the UBE2C promoter and transcriptionally activates UBE2C expression. Site-directed mutations in the FOXM1-binding site markedly reduce UBE2C promoter activity. FOXM1 and UBE2C expression are positively correlated across 25 tumor types. Chromatin immunoprecipitation; promoter-reporter assay with site-directed mutagenesis; siRNA knockdown; gene expression correlation analysis Genes Medium 29596365
2019 UBE2C promotes ubiquitination and degradation of p53 in endometrial cancer cells, thereby reducing p53 and p21 levels and enabling EMT. Estradiol induces UBE2C expression via estrogen receptor α, which directly binds the UBE2C promoter element. p53 overexpression reverses UBE2C-driven EMT. Co-immunoprecipitation; ubiquitination assay; ChIP (ERα binding to UBE2C promoter); Western blotting; siRNA knockdown; in vivo xenograft Molecular cancer research : MCR Medium 31662448
2019 UBE2C increases HIF-1α levels by ubiquitinating and promoting degradation of pVHL (von Hippel-Lindau protein), thereby promoting endothelial inflammation and endothelial-mesenchymal transition in aortic valve endothelial cells exposed to disturbed flow. Ubiquitination/co-immunoprecipitation assays; Western blotting; siRNA knockdown; flow-conditioning of human AV endothelial cells; porcine AV leaflet ex vivo model Arteriosclerosis, thrombosis, and vascular biology Medium 30602302
2023 UBE2C couples with APC/C-CDH1 to promote K11-linked ubiquitylation and degradation of DEPTOR, leading to mTORC1 pathway activation. DEPTOR levels oscillate during the cell cycle in a UBE2C- and CDH1-dependent manner. In a KrasG12D lung tumor model, Ube2c deletion inhibited tumor formation; Deptor deletion fully rescued this inhibitory effect, establishing a causal UBE2C→CDH1→DEPTOR→mTOR oncogenic cascade. In vivo conditional knockout (Ube2c and Deptor deletions in KrasG12D mice); ubiquitylation assay (K11-linkage); co-immunoprecipitation; cell cycle synchronization with protein level tracking The Journal of clinical investigation High 36548081
2023 UBE2C mediates K48-linked ubiquitination of SIRT1, promoting its proteasomal degradation. Loss of SIRT1 reduces H4K16 deacetylation, epigenetically repressing autophagy-related gene expression. This UBE2C-SIRT1-autophagy axis contributes to endometrial cancer progression, and rapamycin (autophagy agonist) reverses tumor growth caused by UBE2C overexpression. Co-immunoprecipitation; ubiquitin immunoprecipitation (K48 linkage); autophagic flux assays (mRFP-GFP-LC3, bafilomycin A1); ChIP for H4K16 acetylation; xenograft model Molecular cancer research : MCR Medium 36930831
2024 UBE2C mediates monoubiquitination of SNAT2 at K59, which competitively inhibits K63-linked polyubiquitination of SNAT2 at K33. This monoubiquitination/K63-polyubiquitination crosstalk suppresses EPN1-mediated endocytosis of SNAT2, increasing SNAT2 membrane levels, enhancing glutamine uptake and VEGFC secretion, and promoting lymphangiogenesis and lymph node metastasis in bladder cancer. High-throughput sequencing; site-specific ubiquitination assays (K59 and K33 mutants); co-immunoprecipitation; endocytosis assay; patient-derived xenograft model; in vitro and in vivo lymphangiogenesis assays The Journal of clinical investigation High 38949026
2010 In HPV-16 E6/E7-expressing keratinocytes, elevated levels of UbcH10 and Cdc20 drive APC/C-dependent cyclin B degradation, allowing these cells to exit mitosis in the presence of DNA damage and bypass the spindle assembly checkpoint. Western blotting; co-immunoprecipitation (Cdc20-BubR1 complexes); cell cycle analysis; cyclin B stability assay Journal of virology Medium 20739533
2022 KAT2A cooperates with E2F1 and is recruited by E2F1 to the UBE2C promoter; this increases H3K9 acetylation at the UBE2C locus, elevating UBE2C transcription and promoting cancer cell proliferation and migration. ChIP assay; immunofluorescence co-localization; RNA-seq; qRT-PCR; Western blotting; cell proliferation/migration assays Genes Medium 36292703
2018 UBE2C directly binds to the 5'-UTR of ZEB1 and ZEB2 transcripts (confirmed by ChIP and luciferase reporter assay), transcriptionally promoting their expression to drive EMT and cisplatin resistance in NSCLC cells. Chromatin immunoprecipitation; luciferase reporter assay; siRNA knockdown; Western blotting; cell migration/invasion assay Theranostics Low 31037155
2024 UBE2C activates Notch signaling in hepatocellular carcinoma by upregulating N1ICD and Hes1 and activating the RBP-JK luciferase reporter. Notch inhibitor DAPT abrogates UBE2C-driven oncogenic phenotypes, and N1ICD overexpression rescues the effect of UBE2C knockdown. RBP-JK luciferase reporter assay; Western blotting; siRNA knockdown and overexpression; Notch inhibitor rescue experiments Scientific reports Low 39353974
2022 UBE2C binds to EGFR, stabilizing it and promoting PI3K-Akt pathway activation in pancreatic cancer cells; UBE2C knockdown impairs glucose uptake, lactate production, and ATP generation, linking UBE2C to glycolytic reprogramming via EGFR stabilization. Co-immunoprecipitation; qRT-PCR; glycolysis metabolite assays (glucose uptake, lactate, ATP); Western blotting; siRNA knockdown Journal of gastrointestinal oncology Low 35837197
2024 UBE2C inhibits gastric cancer cell autophagy by promoting accumulation of p62, which increases p62-KEAP1 interaction and thereby reduces KEAP1-NRF2 binding, weakening NRF2 ubiquitination and degradation and causing nuclear accumulation of NRF2. TBHQ (NRF2 activator) rescues proliferation/migration inhibited by UBE2C silencing. Co-immunoprecipitation; Western blotting; autophagy flux assay; siRNA knockdown and overexpression; rescue with NRF2 activator International journal of biological macromolecules Low 39032892

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1997 Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. Proceedings of the National Academy of Sciences of the United States of America 205 9122200
2010 Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation. The Journal of cell biology 180 20065091
2003 UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer research 160 12874022
2011 Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 125 22170434
2004 Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene 116 15208666
2011 Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. The EMBO journal 111 21556051
2019 UBE2C Is Upregulated by Estrogen and Promotes Epithelial-Mesenchymal Transition via p53 in Endometrial Cancer. Molecular cancer research : MCR 102 31662448
2005 UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. British journal of cancer 100 16106252
2018 Deregulation of UBE2C-mediated autophagy repression aggravates NSCLC progression. Oncogenesis 97 29904125
2008 The unique N terminus of the UbcH10 E2 enzyme controls the threshold for APC activation and enhances checkpoint regulation of the APC. Molecular cell 92 18722180
2011 Nitric oxide inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia by increasing the ubiquitination and degradation of UbcH10. Cell biochemistry and biophysics 74 21448667
2017 UBE2C induces EMT through Wnt/β‑catenin and PI3K/Akt signaling pathways by regulating phosphorylation levels of Aurora-A. International journal of oncology 72 28260026
2019 Disturbed Flow Increases UBE2C (Ubiquitin E2 Ligase C) via Loss of miR-483-3p, Inducing Aortic Valve Calcification by the pVHL (von Hippel-Lindau Protein) and HIF-1α (Hypoxia-Inducible Factor-1α) Pathway in Endothelial Cells. Arteriosclerosis, thrombosis, and vascular biology 67 30602302
2009 Overexpression of UbcH10 alternates the cell cycle profile and accelerate the tumor proliferation in colon cancer. BMC cancer 65 19302711
2023 The UBE2C/CDH1/DEPTOR axis is an oncogene and tumor suppressor cascade in lung cancer cells. The Journal of clinical investigation 64 36548081
2019 UBE2C functions as a potential oncogene by enhancing cell proliferation, migration, invasion, and drug resistance in hepatocellular carcinoma cells. Bioscience reports 64 30914455
2007 UbcH10 is overexpressed in malignant breast carcinomas. European journal of cancer (Oxford, England : 1990) 62 17933517
2013 Additive effect of the AZGP1, PIP, S100A8 and UBE2C molecular biomarkers improves outcome prediction in breast carcinoma. International journal of cancer 60 24114735
2011 Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma. The American journal of pathology 60 21514426
2018 UBE2C Is a Potential Biomarker of Intestinal-Type Gastric Cancer With Chromosomal Instability. Frontiers in pharmacology 58 30116193
2017 The clinicopathological significance of UBE2C in breast cancer: a study based on immunohistochemistry, microarray and RNA-sequencing data. Cancer cell international 57 29021715
2002 Structural and functional analysis of the human mitotic-specific ubiquitin-conjugating enzyme, UbcH10. The Journal of biological chemistry 56 11927573
2018 The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells. EBioMedicine 54 30146342
2019 Depletion of UBE2C reduces ovarian cancer malignancy and reverses cisplatin resistance via downregulating CDK1. Biochemical and biophysical research communications 52 31875843
2013 High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression. BMC cancer 52 23587173
2011 CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability. Cancer research 52 21593191
2013 Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole. Cellular oncology (Dordrecht, Netherlands) 46 24072565
2021 UBE2C affects breast cancer proliferation through the AKT/mTOR signaling pathway. Chinese medical journal 45 34620747
2018 UBE2C Is a Transcriptional Target of the Cell Cycle Regulator FOXM1. Genes 45 29596365
2017 Forkhead Box M1 positively regulates UBE2C and protects glioma cells from autophagic death. Cell cycle (Georgetown, Tex.) 45 28767320
2020 UBE2C Drives Human Cervical Cancer Progression and Is Positively Modulated by mTOR. Biomolecules 44 33396624
2009 Association of clinicopathological features with UbcH10 expression in colorectal cancer. Journal of cancer research and clinical oncology 44 19779934
2008 Expression of ubiquitin-conjugating enzyme E2C/UbcH10 in astrocytic tumors. Brain research 44 18331723
2008 Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma. Endocrine-related cancer 44 18753363
2021 DNA primase subunit 1 deteriorated progression of hepatocellular carcinoma by activating AKT/mTOR signaling and UBE2C-mediated P53 ubiquitination. Cell & bioscience 43 33622397
2016 High expression of UBE2C is associated with the aggressive progression and poor outcome of malignant glioma. Oncology letters 43 26998166
2006 Detection of aberrations of ubiquitin-conjugating enzyme E2C gene (UBE2C) in advanced colon cancer with liver metastases by DNA microarray and two-color FISH. Cancer genetics and cytogenetics 42 16772118
2019 Anticancer effect of icaritin on prostate cancer via regulating miR-381-3p and its target gene UBE2C. Cancer medicine 40 31646760
2019 UBE2C promotes the progression of head and neck squamous cell carcinoma. Biochemical and biophysical research communications 40 31870550
2009 Knockdown of ubiquitin-conjugating enzyme E2C/UbcH10 expression by RNA interference inhibits glioma cell proliferation and enhances cell apoptosis in vitro. Journal of cancer research and clinical oncology 40 19657671
2019 UBE2C overexpression in melanoma and its essential role in G2/M transition. Journal of Cancer 39 31258721
2014 Ubiquitin-conjugating enzyme UBE2C is highly expressed in breast microcalcification lesions. PloS one 39 24699941
2019 MiR-525-5p Repressed Metastasis and Anoikis Resistance in Cervical Cancer via Blocking UBE2C/ZEB1/2 Signal Axis. Digestive diseases and sciences 38 31679088
2002 Molecular characterization of plant ubiquitin-conjugating enzymes belonging to the UbcP4/E2-C/UBCx/UbcH10 gene family. Plant physiology 38 12427990
2016 SAG/RBX2 E3 ligase complexes with UBCH10 and UBE2S E2s to ubiquitylate β-TrCP1 via K11-linkage for degradation. Scientific reports 37 27910872
2018 UBE2C promotes rectal carcinoma via miR-381. Cancer biology & therapy 36 29303411
2016 UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria. Oncotarget 35 27528424
2016 UBE2C is overexpressed in ESCC tissues and its abrogation attenuates the malignant phenotype of ESCC cell lines. Oncotarget 35 27588470
2012 Immunohistochemical analysis of the ubiquitin-conjugating enzyme UbcH10 in lung cancer: a useful tool for diagnosis and therapy. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 35 22388643
2017 Exceptionally high UBE2C expression is a unique phenomenon in basal-like type breast cancer and is regulated by BRCA1. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 33 28881292
2020 UBE2C Overexpression Aggravates Patient Outcome by Promoting Estrogen-Dependent/Independent Cell Proliferation in Early Hormone Receptor-Positive and HER2-Negative Breast Cancer. Frontiers in oncology 32 32039034
2019 UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells. Journal of oncology 32 30693031
2019 UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC. Theranostics 32 31037155
2015 Inhibition of microRNA-17/20a suppresses cell proliferation in gastric cancer by modulating UBE2C expression. Oncology reports 31 25760688
2022 Ubiquitin conjugating enzyme E2 C (UBE2C) may play a dual role involved in the progression of thyroid carcinoma. Cell death discovery 29 35332135
2016 E2 Ubiquitin-conjugating Enzyme, UBE2C Gene, Is Reciprocally Regulated by Wild-type and Gain-of-Function Mutant p53. The Journal of biological chemistry 29 27129209
2009 UbcH10 expression in human lymphomas. Histopathology 29 19438748
2015 Appropriate expression of Ube2C and Ube2S controls the progression of the first meiotic division. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 28 26207029
2012 UbcH10 overexpression in human lung carcinomas and its correlation with EGFR and p53 mutational status. European journal of cancer (Oxford, England : 1990) 28 23102841
2016 hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10. Oncology reports 26 28000886
2015 MicroRNA-196a post-transcriptionally upregulates the UBE2C proto-oncogene and promotes cell proliferation in breast cancer. Oncology reports 26 26062455
2014 UbcH10 overexpression increases carcinogenesis and blocks ALLN susceptibility in colorectal cancer. Scientific reports 26 25376843
2008 Analysis of UbcH10 expression represents a useful tool for the diagnosis and therapy of astrocytic tumors. Clinical neuropathology 26 18666437
2020 UbcH10 a Major Actor in Cancerogenesis and a Potential Tool for Diagnosis and Therapy. International journal of molecular sciences 25 32192022
2023 UBE2C-mediated Autophagy Inhibition via Ubiquitination of SIRT1 Contributes to Endometrial Cancer Progression. Molecular cancer research : MCR 24 36930831
2019 Identification of the potential therapeutic target gene UBE2C in human hepatocellular carcinoma: An investigation based on GEO and TCGA databases. Oncology letters 24 31186759
2010 Compromised spindle assembly checkpoint due to altered expression of Ubch10 and Cdc20 in human papillomavirus type 16 E6- and E7-expressing keratinocytes. Journal of virology 24 20739533
2009 Clinicopathological relevance of UbcH10 in breast cancer. Cancer science 24 19038004
2019 Combined elevation of AURKB and UBE2C predicts severe outcomes and therapy resistance in glioma. Pathology, research and practice 23 31353228
2017 UBE2C is involved in the functions of ECRG4 on esophageal squamous cell carcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 23 29268240
2016 Ubiquitin-conjugating enzyme UbcH10 promotes gastric cancer growth and is a potential biomarker for gastric cancer. Oncology reports 23 27349176
2015 Knockdown of UbcH10 enhances the chemosensitivity of dual drug resistant breast cancer cells to epirubicin and docetaxel. International journal of molecular sciences 23 25739083
2011 Spindle assembly checkpoint protein Cdc20 transcriptionally activates expression of ubiquitin carrier protein UbcH10. The Journal of biological chemistry 23 21454660
2023 Role of UBE2C in Brain Cancer Invasion and Dissemination. International journal of molecular sciences 22 37958776
2022 UBE2C promotes the progression of pancreatic cancer and glycolytic activity via EGFR stabilization-mediated PI3K-Akt pathway activation. Journal of gastrointestinal oncology 22 35837197
2022 KAT2A/E2F1 Promotes Cell Proliferation and Migration via Upregulating the Expression of UBE2C in Pan-Cancer. Genes 21 36292703
2021 Molecular subtyping and functional validation of TTK, TPX2, UBE2C, and LRP8 in sensitivity of TNBC to paclitaxel. Molecular therapy. Methods & clinical development 21 33665229
2023 FOXM1-regulated ZIC2 promotes the malignant phenotype of renal clear cell carcinoma by activating UBE2C/mTOR signaling pathway. International journal of biological sciences 20 37496990
2021 Vorinostat targets UBE2C to reverse epithelial-mesenchymal transition and control cervical cancer growth through the ubiquitination pathway. European journal of pharmacology 20 34331954
2021 The Relationship Between UBE2C and AGGF1 Overexpression and Tumor Angiogenesis in Non-Small Cell Lung Cancer. Cancer management and research 20 34354374
2023 Identification of transcriptome characteristics of granulosa cells and the possible role of UBE2C in the pathogenesis of premature ovarian insufficiency. Journal of ovarian research 18 37848988
2020 UBE2C mRNA expression controlled by miR-300 and HuR determines its oncogenic role in gastric cancer. Biochemical and biophysical research communications 18 33223052
2018 Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer. Cancer medicine 18 29575713
2010 RNA interference-mediated silencing of UBCH10 gene inhibits colorectal cancer cell growth in vitro and in vivo. Clinical and experimental pharmacology & physiology 18 20529090
2010 UbcH10 expression on thyroid fine-needle aspirates. Cancer cytopathology 17 20544706
2024 Curcumin inhibits prostate cancer by upregulating miR-483-3p and inhibiting UBE2C. Journal of biochemical and molecular toxicology 16 38348716
2024 UBE2C-induced crosstalk between mono- and polyubiquitination of SNAT2 promotes lymphatic metastasis in bladder cancer. The Journal of clinical investigation 16 38949026
2022 UBE2C triggers HIF-1α-glycolytic flux in head and neck squamous cell carcinoma. Journal of cellular and molecular medicine 16 35615976
2022 Overexpressed lncRNA FTX promotes the cell viability, proliferation, migration and invasion of renal cell carcinoma via FTX/miR‑4429/UBE2C axis. Oncology reports 16 35866591
2024 UBE2C regulates the KEAP1/NRF2 signaling pathway to promote the growth of gastric cancer by inhibiting autophagy. International journal of biological macromolecules 14 39032892
2018 Contributions of UBE2C and UBE2S to meiotic progression of porcine oocytes. The Journal of reproduction and development 14 29576589
2021 The clinical significance of <em>UBE2C</em> gene in progression of renal cell carcinoma. European journal of histochemistry : EJH 13 33782624
2015 High EGFR_1 Inside-Out Activated Inflammation-Induced Motility through SLC2A1-CCNB2-HMMR-KIF11-NUSAP1-PRC1-UBE2C. Journal of Cancer 12 26000042
2011 A study of UbcH10 expression and its association with recurrence of meningiomas. Journal of surgical oncology 12 22095464
2005 A novel UbcH10-binding protein facilitates the ubiquitinylation of cyclin B in vitro. Journal of biochemistry 12 15749827
2023 Comprehensive analysis of UBE2C expression and its potential roles and mechanisms in hepatocellular carcinoma. Aging 11 37580802
2021 LncRNA MALAT1 Regulating Lung Carcinoma Progression via the miR-491-5p/UBE2C Axis. Pathology oncology research : POR 11 34257576
2021 Overexpression of UBE2C in esophageal squamous cell carcinoma tissues and molecular analysis. BMC cancer 11 34488675
2020 KIAA0101 and UbcH10 interact to regulate non-small cell lung cancer cell proliferation by disrupting the function of the spindle assembly checkpoint. BMC cancer 11 33008389
2024 The activation of the Notch signaling pathway by UBE2C promotes the proliferation and metastasis of hepatocellular carcinoma. Scientific reports 10 39353974

Missed literature

Know a paper Affinage missed for UBE2C? Flag it for the maintainers and the community.

No submissions yet.